A citation-based method for searching scientific literature

John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
Times Cited: 389







List of co-cited articles
1122 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Cristian Guja, Juan P Frías, Aniko Somogyi, Serge Jabbour, Hui Wang, Elise Hardy, Julio Rosenstock. Diabetes Obes Metab 2018
23
39

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Richard Bergenstal, Andrew Lewin, Timothy Bailey, Denise Chang, Titus Gylvin, Victor Roberts. Curr Med Res Opin 2009
69
11

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
8


Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.
M A Bush, J E Matthews, E H De Boever, R L Dobbins, R J Hodge, S E Walker, M C Holland, M Gutierrez, M W Stewart. Diabetes Obes Metab 2009
123
8

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Tina Vilsbøll, Mikkel Christensen, Anders E Junker, Filip K Knop, Lise Lotte Gluud. BMJ 2012
514
8

Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
Louise E Robinson, Tim A Holt, Karen Rees, Harpal S Randeva, Joseph P O'Hare. BMJ Open 2013
199
8

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
8

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).
Bernard Zinman, Athena Philis-Tsimikas, Bertrand Cariou, Yehuda Handelsman, Helena W Rodbard, Thue Johansen, Lars Endahl, Chantal Mathieu. Diabetes Care 2012
224
8

A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.
Mayer B Davidson, Philip Raskin, Robert J Tanenberg, Aleksandra Vlajnic, Pricilla Hollander. Endocr Pract 2011
71
11

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
Hannele Yki-Järvinen, Julio Rosenstock, Santiago Durán-Garcia, Sabine Pinnetti, Sudipta Bhattacharya, Sandra Thiemann, Sanjay Patel, Hans-Juergen Woerle. Diabetes Care 2013
105
8

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
Rury R Holman, Kerensa I Thorne, Andrew J Farmer, Melanie J Davies, Joanne F Keenan, Sanjoy Paul, Jonathan C Levy. N Engl J Med 2007
477
8


Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
Richard E Pratley, Michael Nauck, Timothy Bailey, Eduard Montanya, Robert Cuddihy, Sebastiano Filetti, Anne Bloch Thomsen, Rie Elvang Søndergaard, Melanie Davies. Lancet 2010
428
8

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).
Francesco Giorgino, Marian Benroubi, Jui-Hung Sun, Alan G Zimmermann, Valeria Pechtner. Diabetes Care 2015
128
8

Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
Julio Rosenstock, Markolf Hanefeld, Paramesh Shamanna, Kyung Wan Min, Gabor Boka, Patrick Miossec, Tianyue Zhou, Isabel Muehlen-Bartmer, Robert E Ratner. J Diabetes Complications 2014
86
9



Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus.
H Yki-Järvinen, M Kauppila, E Kujansuu, J Lahti, T Marjanen, L Niskanen, S Rajala, L Ryysy, S Salo, P Seppälä. N Engl J Med 1992
270
8


Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Anna Vanderheiden, Lindsay Harrison, Jeremy Warshauer, Xilong Li, Beverley Adams-Huet, Ildiko Lingvay. JAMA Intern Med 2016
20
40


Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.
Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetologia 2015
449
7

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks.
Takashi Kadowaki, Mitsuyoshi Namba, Takeshi Imaoka, Ayuko Yamamura, Wakana Goto, Marilyn K Boardman, Hideaki Sowa. J Diabetes Investig 2011
43
16

Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.
Mahesh M Umapathysivam, Michael Y Lee, Karen L Jones, Christopher E Annink, Caroline E Cousins, Laurence G Trahair, Chris K Rayner, Marianne J Chapman, Michael A Nauck, Michael Horowitz,[...]. Diabetes 2014
79
8

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.
Baptist Gallwitz, Michael Böhmer, Thomas Segiet, Andrea Mölle, Karsten Milek, Bernd Becker, Karin Helsberg, Helmut Petto, Natalie Peters, Oliver Bachmann. Diabetes Care 2011
64
10

Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
David Russell-Jones, Rehman Khan. Diabetes Obes Metab 2007
312
7

Glucose control and vascular complications in veterans with type 2 diabetes.
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
7

Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
Bernard Charbonnel, Monica Bertolini, Francisco J Tinahones, Manuel Puig Domingo, Melanie Davies. J Diabetes Complications 2014
37
18

Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).
Bo Ahrén, Aniceto Leguizamo Dimas, Patrick Miossec, Stéphane Saubadu, Ronnie Aronson. Diabetes Care 2013
123
7

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Alan J Garber, Allen B King, Stefano Del Prato, Seamus Sreenan, Mustafa K Balci, Manuel Muñoz-Torres, Julio Rosenstock, Lars A Endahl, Ann Marie Ocampo Francisco, Priscilla Hollander. Lancet 2012
234
7

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Michael A Nauck, Guido Kemmeries, Jens J Holst, Juris J Meier. Diabetes 2011
212
7

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.
Julio Rosenstock, George Dailey, Massimo Massi-Benedetti, Andreas Fritsche, Zhengning Lin, Alan Salzman. Diabetes Care 2005
259
7


Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A Dormandy, Bernard Charbonnel, David J A Eckland, Erland Erdmann, Massimo Massi-Benedetti, Ian K Moules, Allan M Skene, Meng H Tan, Pierre J Lefèbvre, Gordon D Murray,[...]. Lancet 2005
7

One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
Julio Rosenstock, Helena W Rodbard, Stephen C Bain, David D'Alessio, Jochen Seufert, Anne B Thomsen, Claus Bo Svendsen, J Hans DeVries. J Diabetes Complications 2013
33
21

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger,[...]. Endocr Pract 2016
168
7

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
William C Knowler, Elizabeth Barrett-Connor, Sarah E Fowler, Richard F Hamman, John M Lachin, Elizabeth A Walker, David M Nathan. N Engl J Med 2002
7

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
James D Lewis, Laurel A Habel, Charles P Quesenberry, Brian L Strom, Tiffany Peng, Monique M Hedderson, Samantha F Ehrlich, Ronac Mamtani, Warren Bilker, David J Vaughn,[...]. JAMA 2015
186
7

Insulin analogues.
Irl B Hirsch. N Engl J Med 2005
525
7

Severe hypoglycemia and risks of vascular events and death.
Sophia Zoungas, Anushka Patel, John Chalmers, Bastiaan E de Galan, Qiang Li, Laurent Billot, Mark Woodward, Toshiharu Ninomiya, Bruce Neal, Stephen MacMahon,[...]. N Engl J Med 2010
936
7

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Steven E Kahn, Bernard Zinman, John M Lachin, Steven M Haffner, William H Herman, Rury R Holman, Barbara G Kravitz, Dahong Yu, Mark A Heise, R Paul Aftring,[...]. Diabetes Care 2008
373
7

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.
M Hanefeld, M Cagatay, T Petrowitsch, D Neuser, D Petzinna, M Rupp. Eur Heart J 2004
455
7

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Jean-Louis Chiasson, Robert G Josse, Ramon Gomis, Markolf Hanefeld, Avraham Karasik, Markku Laakso. JAMA 2003
7

Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes.
Rodney A Hayward, Peter D Reaven, Wyndy L Wiitala, Gideon D Bahn, Domenic J Reda, Ling Ge, Madeline McCarren, William C Duckworth, Nicholas V Emanuele. N Engl J Med 2015
364
7

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
427
7



CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.
Alan J Garber, Martin J Abrahamson, Joshua I Barzilay, Lawrence Blonde, Zachary T Bloomgarden, Michael A Bush, Samuel Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Vivian A Fonseca,[...]. Endocr Pract 2016
309
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.